Collaborative Arrangements (Tables)

3 Months Ended

Mar. 31, 2022

Collaborative Arrangements [Abstract]

Summarized financial information related to this collaboration is as follows:


	Three Months Ended March 31,
($ in millions)	2022		2021
Alliance revenue - Lynparza	$	266	$	228
Alliance revenue - Koselugo	9		5
Total alliance revenue	$	275	$	233

Cost of sales (1)	299		42
Selling, general and administrative	44		40
Research and development	26		29

($ in millions)	March 31, 2022		December 31, 2021
Receivables from AstraZeneca included in Other current assets	$	275	$	271
Payables to AstraZeneca included in Trade accounts payable and Accrued and other current liabilities (2)	190		415
Payables to AstraZeneca included in Other Noncurrent Liabilities (2)	600		—

(1) Represents amortization of capitalized milestone payments. Amount in the first quarter of 2022 includes $250 million of cumulative amortization catch-up expense as noted above.

(2) Includes accrued milestone payments.

Summarized financial information related to this collaboration is as follows:


	Three Months Ended March 31,
($ in millions)	2022		2021
Alliance revenue - Lenvima	$	227	$	130

Cost of sales (1)	53		47
Selling, general and administrative	31		23
Research and development	57		64

($ in millions)	March 31, 2022		December 31, 2021
Receivables from Eisai included in Other current assets	$	241	$	200
Payables to Eisai included in Accrued and other current liabilities (2)	325		625

(1) Represents amortization of capitalized milestone payments.

(2) Includes accrued milestone payments.

Summarized financial information related to this collaboration is as follows:


	Three Months Ended March 31,
($ in millions)	2022		2021
Alliance revenue - Adempas/Verquvo	$	72	$	74
Net sales of Adempas recorded by Merck	61		55
Net sales of Verquvo recorded by Merck	3		—
Total sales	$	136	$	129

Cost of sales (1)	50		208
Selling, general and administrative	23		17
Research and development	17		7
($ in millions)	March 31, 2022		December 31, 2021
Receivables from Bayer included in Other current assets	$	129	$	114
Payables to Bayer included in Accrued and other current liabilities (2)	74		472

(1) Includes amortization of intangible assets. Amount in the first quarter of 2021 includes $153 million of cumulative amortization catch-up expense. In addition, cost of sales includes Bayer’s share of profits from sales in Merck’s marketing territories.

(2) Amount as of December 31, 2021 includes accrued milestone payment.

Summarized financial information related to this collaboration is as follows:


	Three Months Ended March 31,
($ in millions)	2022		2021
Lagevrio sales	$	3,247	$	—

Cost of sales (1)	1,724		46
Selling, general and administrative	34		3
Research and development	6		42

($ in millions)	March 31, 2022		December 31, 2021
Payables to Ridgeback included in Accrued and other current liabilities (2)	$	1,568	$	283

(1) Includes royalty expense and amortization of capitalized milestone payments.

(2) Includes accrued royalty and milestone payments.